Clinical Trial Update: Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cadonilimab plus lenvatinib as second-line treatment for unresectable hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cadonilimab
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: WITHDRAWN